Clinical Trials Logo

Myotonic Dystrophy 1 clinical trials

View clinical trials related to Myotonic Dystrophy 1.

Filter by:

NCT ID: NCT03141749 Completed - Pulmonary Embolism Clinical Trials

Venous Thromboembolism in DM1

DM1-VTE
Start date: January 2000
Phase: N/A
Study type: Observational

The risk for venous thromboembolism (VTE) in DM1 and in other inherited myopathies, which can lead to chronic immobilization, are unknown. The purpose of this study is to evaluate incidence of VTE in cohort of patients presenting with DM1 with a comparison to a group of other inheritable myopathies and to a community-based population.

NCT ID: NCT02858908 Completed - Clinical trials for Myotonic Dystrophy 1

Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

Start date: July 20, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Tideglusib is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy. The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.

NCT ID: NCT02729597 Completed - Clinical trials for Myotonic Dystrophy 1

Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study

Start date: May 2007
Phase: N/A
Study type: Observational

The natural history of brain affection in myotonic dystrophy types 1 and 2 is still unknown. The investigators designed a 5-year longitudinal neuropsychological and neuroimaging follow-up study to address this issue. Myotonic dystrophy type 1, myotonic dystrophy type 2 patients, and healthy controls were enrolled. All participants undergo clinical-neurological examinations, neuropsychological analyses according to a 13-item neuropsychological test battery, and 3T-brain MRI including voxel-based morphometry and diffusion tensor imaging at baseline and at follow-up using identical examination protocols.

NCT ID: NCT02251457 Completed - Clinical trials for Myotonic Dystrophy 1

Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1

Start date: August 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to gather preliminary data to determine if ranolazine is a safe and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and myotonic dystrophy type 1. The duration of the study is 5 weeks.